Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819254 · ClinicalTrials.gov registry record · Phase 4
Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
A Phase 4 study of Fatigue, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06819254: Recruiting Phase 4 study of Fatigue, sponsored by Wake Forest University Health Sciences.
NCT06819254 is a Phase 4 study of Fatigue that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 60 participants, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06819254, a Phase 4 study of Fatigue, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if taking a Fisetin supplement can decrease fatigue among older cancer survivors.
Primary Outcome
10-item PFS score is a measure of perceived fatigability in older adults and can serve as an adjunct to performance-based fatigability measures for identifying older adults at risk of mobility limitation in clinical and research settings. Total score range is 0-50 with higher score indicating greater fatigue.
Conditions Studied
Interventions
- DRUG Fisetin followed by Placebo
- DRUG Placebo followed by Fisetin
Study Locations (1)
North Carolina
- Atrium Health Wake Forest Baptist Hospital - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT06819254 shows while recruiting
NCT06819254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Fisetin followed by Placebo is the first listed.
NCT06819254 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06819254 about?
NCT06819254 is a clinical study titled "Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors". The purpose of this study is to find out if taking a Fisetin supplement can decrease fatigue among older cancer survivors.
What is the current status of trial NCT06819254?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2025-12-09. Estimated completion is 2026-12-31.
What conditions does trial NCT06819254 study?
This clinical trial studies the following conditions: Fatigue.
What interventions are being tested in trial NCT06819254?
The interventions under investigation include: Fisetin followed by Placebo (DRUG), Placebo followed by Fisetin (DRUG).
Who is sponsoring clinical trial NCT06819254?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819254 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06819254's enrollment target sits among peer trials
60 56th of 109 higher than 52 of 109 other Fatigue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
RECRUITING · Phase 4
-
Fatigue and Cognitive Demand With Aging
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Behavioral and Neural Correlates of Post-Stroke Fatigue
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
-
Eccentric Exercise and Fatigue in Multiple Sclerosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI